Form 4: Neuraxis CMO Granted 47,569 RSUs

Neuraxis, Inc. Chief Medical Officer and SVP of Science & Technology, Adrian Miranda, was granted 47,569 restricted stock units as compensation.

Summary

• Adrian Miranda, CMO and SVP Science & Tech of Neuraxis, Inc. (NRXS), was granted 47,569 Restricted Stock Units (RSUs).
• The grant occurred on January 22, 2026.
• These RSUs were issued as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended.
• The RSUs vest in three equal annual installments over a three-year period.
• The implied value per RSU at grant was $4.63.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with long-term shareholder value, without indicating any immediate operational or financial breakthroughs.

Positives

• Grant of 47,569 Restricted Stock Units (RSUs) to a key executive, Adrian Miranda, aligns management incentives with shareholder interests.
• The RSUs are part of the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedule of the RSUs over a three-year period suggests a long-term incentive for the executive, aligning their future performance with the company's success.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units (RSUs) with multi-year vesting schedules, are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key scientific and executive talent. This grant to Neuraxis's CMO and SVP Science & Tech is consistent with industry norms for executive compensation, aiming to align leadership interests with long-term shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a compensation mechanism is a common practice across the biotechnology and pharmaceutical sectors, similar to companies like Biogen, Gilead Sciences, and Amgen, which frequently utilize equity awards to incentivize executives.
• A three-year vesting schedule for executive equity grants is standard in the industry, comparable to vesting periods seen at companies such as Moderna for its senior leadership, ensuring long-term commitment and performance alignment.
• The grant size of 47,569 RSUs to a CMO/SVP-level executive at a company like Neuraxis (NRXS) is within the typical range for similar roles in emerging or mid-cap biotech firms, reflecting a competitive compensation package designed to retain high-caliber talent.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from future RSU vesting, but also improved alignment of executive interests with long-term shareholder value.
• Employees: Signals continued commitment to executive talent, potentially boosting morale and demonstrating a structured compensation framework.

Next Steps

• The RSUs will vest in three equal annual installments over a three-year period, implying future share issuances upon vesting.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant and does not provide new information that would fundamentally alter the investment thesis for Neuraxis. While positive for executive retention and alignment, it does not indicate a significant operational or financial catalyst for a 'buy' or 'sell' recommendation. Investors should continue to 'hold' and monitor broader company performance and market conditions.

Keywords

Neuraxis, NRXS, Adrian Miranda, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant